Chugai Pharmaceutical Co., Ltd.
4519
Kedudukan dalam Saham
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Harga Saham
$41.60
Modal Pasaran
$68.46B
Perubahan (1 hari)
0.94%
Perubahan (1 tahun)
-12.56%
Negara
JP
Perdagangan Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
Pendapatan untuk Chugai Pharmaceutical Co., Ltd. (4519)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Chugai Pharmaceutical Co., Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Chugai Pharmaceutical Co., Ltd. dari 2003 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2025 | $3.81B | 10.18% |
| 2024 | $3.46B | 9.91% |
| 2023 | $3.15B | -22.32% |
| 2022 | $4.05B | 11.19% |
| 2021 | $3.64B | 26.14% |
| 2020 | $2.89B | 51.00% |
| 2019 | $1.91B | 72.67% |
| 2018 | $1.11B | 28.63% |
| 2017 | $861.20M | 35.29% |
| 2016 | $636.58M | -12.20% |
| 2015 | $725.04M | 14.00% |
| 2014 | $635.98M | -12.96% |
| 2013 | $730.71M | -13.05% |
| 2012 | $840.36M | 13.52% |
| 2011 | $740.25M | -8.49% |
| 2010 | $808.92M | -16.02% |
| 2009 | $963.18M | 38.51% |
| 2008 | $695.38M | 17.04% |
| 2007 | $594.11M | 12.26% |
| 2006 | $529.22M | -27.64% |
| 2005 | $731.36M | 30.51% |
| 2004 | $560.37M | 21.93% |
| 2003 | $459.59M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
